Abstract
Variations in the capacity to detoxify carcinogens and other environmental toxins, and to eliminate drugs and waste products of metabolism, are likely to have significant effects on health and drug efficacy. As the UDP glucuronosyltransferases metabolize many of these substances to less toxic glucuronides, variations in UGT expression are likely to be important in maintenance of health and therapeutic outcomes. The factors that regulate UGT gene expression are beginning to be identified. From among these factors, the Liver-Enriched Transcription Factors (LETFs), including Hepatocyte Nuclear Factors 1 and 4α, have a major role in UGT regulation in the major sites of drug metabolism, the liver and gastrointestinal tract. This review will describe what is currently known about these LETFs and their role in UGT gene expression. It is likely that polymorphisms in LETFs and the sites to which they bind in UGT genes, may impact on drug induced disease and drug therapy.
Keywords: UDP glucuronosyltransferase, liver-enriched transcription factors, hepatocyte nuclear factor, CAAT-enhancer binding protein, gene regulation
Current Drug Metabolism
Title: Liver-Enriched Transcription Factors and Their Role in Regulating UDP Glucuronosyltransferase Gene Expression
Volume: 9 Issue: 5
Author(s): D. A. Gardner-Stephen and P. I. Mackenzie
Affiliation:
Keywords: UDP glucuronosyltransferase, liver-enriched transcription factors, hepatocyte nuclear factor, CAAT-enhancer binding protein, gene regulation
Abstract: Variations in the capacity to detoxify carcinogens and other environmental toxins, and to eliminate drugs and waste products of metabolism, are likely to have significant effects on health and drug efficacy. As the UDP glucuronosyltransferases metabolize many of these substances to less toxic glucuronides, variations in UGT expression are likely to be important in maintenance of health and therapeutic outcomes. The factors that regulate UGT gene expression are beginning to be identified. From among these factors, the Liver-Enriched Transcription Factors (LETFs), including Hepatocyte Nuclear Factors 1 and 4α, have a major role in UGT regulation in the major sites of drug metabolism, the liver and gastrointestinal tract. This review will describe what is currently known about these LETFs and their role in UGT gene expression. It is likely that polymorphisms in LETFs and the sites to which they bind in UGT genes, may impact on drug induced disease and drug therapy.
Export Options
About this article
Cite this article as:
Gardner-Stephen A. D. and Mackenzie I. P., Liver-Enriched Transcription Factors and Their Role in Regulating UDP Glucuronosyltransferase Gene Expression, Current Drug Metabolism 2008; 9 (5) . https://dx.doi.org/10.2174/138920008784746409
DOI https://dx.doi.org/10.2174/138920008784746409 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Defective and Excessive Immunities in Pediatric Diseases
Current Pharmaceutical Design Recent Aspects of Osmotic Pump Systems: Functionalization, Clinical use and Advanced Imaging Technology
Current Drug Metabolism Estrogen Receptors as Therapeutic Targets in Breast Cancer
Current Topics in Medicinal Chemistry 7-Keto-Δ5-Steroids: Key-Molecules Owning Particular Biological and Chemical Interest
Mini-Reviews in Medicinal Chemistry Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis
Inflammation & Allergy - Drug Targets (Discontinued) From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology New Insights on the Xenobiotic-Sensing Nuclear Receptors in Liver Diseases – CAR and PXR-
Current Drug Metabolism Subject Index To Volume 4
Current Pharmacogenomics Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics Exfoliated Epithelial Cells: A Non-Invasive way to Evaluate the Physiological State of Gastrointestinal Epithelium
Recent Patents on Biomedical Engineering (Discontinued) Alpha-1 Antitrypsin: It’s Role in Health and Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Effect of Drugs on the Labeling of Blood Elements with Technetium-99m
Current Pharmaceutical Design Systematic Review of the Role of Microparticles in Systemic Sclerosis
Current Rheumatology Reviews Site Targeted Press Coated Delivery of Methylprednisolone Using Eudragit RS 100 and Chitosan for Treatment of Colitis
Recent Patents on Anti-Infective Drug Discovery Targeted Protein Degradation and Regulation with Molecular Glue: Past and Recent Discoveries
Current Medicinal Chemistry Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Current Drug Targets The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Dysfunction of Mitochondrial ATP Production As a Target for Personalized Cancer Therapy
Current Pharmacogenomics and Personalized Medicine Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design